Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study

SIMPLE SUMMARY: Nivolumab is an anti-PD-1 monoclonal antibody that has been approved in the management of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with evidence of progression within 6 months of platinum-based chemotherapy. Most of the evidence regarding the use of nivoluma...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasiliadou, Ifigenia, Breik, Omar, Baker, Holly, Leslie, Isla, Sim, Van Ren, Hegarty, Gemma, Michaelidou, Andriana, Nathan, Kannon, Hartley, Andrew, Good, James, Sanghera, Paul, Fong, Charles, Urbano, Teresa Guerrero, Lei, Mary, Petkar, Imran, Ferreira, Miguel Reis, Nutting, Chris, Wong, Kee Howe, Newbold, Kate, Harrington, Kevin, Bhide, Shree, Kong, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003537/
https://www.ncbi.nlm.nih.gov/pubmed/33808781
http://dx.doi.org/10.3390/cancers13061413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003537/
https://www.ncbi.nlm.nih.gov/pubmed/33808781
http://dx.doi.org/10.3390/cancers13061413

Ejemplares similares